381 The AspireAssist Is an Effective Tool in the Treatment of Class II and Class III Obesity: Results of a One-Year Clinical Trial

Thompson, Christopher C.; Dayyeh, Barham K. Abu; Kushner, Robert F.; Sullivan, Shelby; Schorr, Alan B.; Amaro, Anastassia; Apovian, Caroline M.; Fullum, Terrence M.; Zarrinpar, Amir; Jensen, Michael D.; Stein, Adam C.; Edmundowicz, Steven A.; Kahaleh, Michel; Ryou, Marvin; Bohning, J. Matthew; Ginsberg, Gregory G.; Huang, Christopher; Tran, Daniel; Martin, John A.; Jaffe, David L.; Farraye, Francis A.; Ho, Samuel B.; Kumar, Nitin; Harakal, Donna; Young, Meredith; Thomas, Catherine E.; Shukla, Alpana; Ryan, Michele B.; Haas, Miki; Goldsmith, Heidi; McCrea, Jennifer; Aronne, Louis J.

doi:10.1016/s0016-5085(16)30406-1

Cited by 23 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the multicenter US "PATHWAY" RCT (n = 111 aspiration group, BMI 42.2 ± 5.1 kg/m 2 vs lifestyle group, n = 60, BMI 40.9 ± 5.1 kg/m 2 ), the modified intention-to-treat analysis weight loss was 12.1 ± 9.6 and 3.5 ± 6.0% TBWL, respectively (p < 0.001). In the completer analysis, weight loss was 14.2 ± 9.8% (aspiration group, n = 82) and 4.9 ± 7.0% TBWL (lifestyle group, n = 31) (p < 0.01) [208]. In a European multisite clinical registry (n = 160), similar TBWL was found, i.e., 1 year, 24.3 ± 13.9% (n = 117); 2 years, 26.6 ± 17.3% (n = 78); 3 years, 30.3 ± 15.3% (n = 23); and 4 years, 25.1 ± 19.1% (n = 12) [209].…”

Section: Indications/contraindications Weight Loss Diabetes Resolutionmentioning

confidence: 97%

Standardization of Bariatric Metabolic Procedures: World Consensus Meeting Statement

Bhandari

Fobi

Buchwald³

2019

OBES SURG

109

View full text Add to dashboard Cite

Background Standardization of the key measurements of a procedure's finished anatomic configuration strengthens surgical practice, research, and patient outcomes. A consensus meeting was organized to define standard versions of 25 bariatric metabolic procedures. Methods A panel of experts in bariatric metabolic surgery from multiple continents was invited to present technique descriptions and outcomes for 4 classic, or conventional, and 21 variant and emerging procedures. Expert panel and audience discussion was followed by electronic voting on proposed standard dimensions and volumes for each procedure's key anatomic alterations. Consensus was defined as ≥ 70% agreement. Results The Bariatric Metabolic Surgery Standardization World Consensus Meeting (BMSS-WOCOM) was convened March 22-24, 2018, in New Delhi, India. Discussion confirmed heterogeneity in procedure measurements in the literature. A set of anatomic measurements to serve as the standard version of each procedure was proposed. After two voting rounds, 22/25 (88.0%) configurations posed for consideration as procedure standards achieved voting consensus by the expert panel, 1 did not attain consensus, and 2 were not voted on. All configurations were voted on by ≥ 50% of 50 expert panelists. The Consensus Statement was developed from scientific evidence collated from presenters' slides and a separate literature review, meeting video, and transcripts. Review and input was provided by consensus panel members. Conclusions Standard versions of the finished anatomic configurations of 22 surgical procedures were established by expert consensus. The BMSS process was undertaken as a first step in developing evidence-based standard bariatric metabolic surgical procedures with the aim of improving consistency in surgery, data collection, comparison of procedures, and outcome reporting.

show abstract

Section: Indications/contraindications Weight Loss Diabetes Resolutionmentioning

confidence: 97%

Standardization of Bariatric Metabolic Procedures: World Consensus Meeting Statement

Bhandari

Fobi

Buchwald³

2019

OBES SURG

109

View full text Add to dashboard Cite

show abstract

“…81 The FDA-approved device, AspireAssist (Aspire Bariatrics, King of Prussia, PA) system, has achieved impressive weight loss metrics in obese patients: 37.2 AE 27.5% excess weight loss compared with 13.0 AE 17.6% seen in the lifestyle modification control group. 82 Potential complications of this weight loss procedure include moderate pain, severe pain, intra-abdominal leakage, site infections, and fistula formation. 81,83 Endoscopic sleeve gastroplasty (ESG) is an EBT that attempts to mimic the effects of LSG by suturing the stomach to reduce stomach lumen size.…”

Section: Endoscopic Weight Loss Therapiesmentioning

confidence: 99%

A Review of Past and Present Weight Loss Strategies and the Potential Role of Bariatric Arterial Embolization

Danda

Bailey

Weiss

2020

Digestive Disease Interventions

View full text Add to dashboard Cite

The obesity epidemic is a growing public health concern that has a severe effect on the health care system with significant morbidity, mortality, and cost. Treatment options for obesity include lifestyle modifications, pharmacotherapy, and bariatric surgery. Newer, less-invasive therapies including endoscopic bariatric procedures have been developed in recent years to fill the treatment gap that exists between noninvasive approaches and surgery. Bariatric artery embolization (BAE) is a novel minimally invasive endovascular procedure that has been developed to treat obesity. Recent evidence has suggested that bariatric embolization is well tolerated and can induce clinically significant weight loss through a hormonally mediated mechanism. This article will review existing preclinical and clinical data, and explore future directions of the endovascular treatment of obesity.

show abstract

“…No evidence of increased food intake or development of abnormal eating behaviors was found. 58 In June 2016, the device was approved by the FDA for long-term implantation.…”

Section: Gastric Endoscopic Proceduresmentioning

confidence: 99%

Endoscopic Bariatric and Metabolic Therapies: Surgical Analogues and Mechanisms of Action

Jirapinyo

Thompson

2017

Clinical Gastroenterology and Hepatology

Self Cite

View full text Add to dashboard Cite

Obesity is a worsening pandemic with numerous related comorbid illnesses. Conservative management including lifestyle modification and medications have limited efficacy. In contradistinction, bariatric surgery is effective, however, with substantial cost and non-negligible morbidity and mortality. As such, a small percentage of eligible patients undergo surgery. Over the past decade, endoscopic bariatric therapies (EBTs) have been introduced as a less invasive option for the treatment of obesity and its related comorbid illnesses. This paper reviews major endoscopic bariatric therapies, their surgical analogues and proposed mechanisms of action. Clinical trial data for each device are also discussed.

show abstract

381 The AspireAssist Is an Effective Tool in the Treatment of Class II and Class III Obesity: Results of a One-Year Clinical Trial

Cited by 23 publications

References 0 publications

Standardization of Bariatric Metabolic Procedures: World Consensus Meeting Statement

Standardization of Bariatric Metabolic Procedures: World Consensus Meeting Statement

A Review of Past and Present Weight Loss Strategies and the Potential Role of Bariatric Arterial Embolization

Endoscopic Bariatric and Metabolic Therapies: Surgical Analogues and Mechanisms of Action

Contact Info

Product

Resources

About